A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma

Clinical trial NCT04036461 · TERMINATED

Trial details

NCT number: NCT04036461
Sponsor: Celgene
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2019-08-26
Primary completion: 2024-07-08
Enrollment: 47

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.